Superworth

Elicio Therapeutics free cash flow ELTX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2020.

Last 12 months, to Dec 31, 2025
n/m
a quarter missing
Latest quarter, Q4 FY25
−$6.8M
Fiscal year 2025
n/a

Elicio Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY25, it was −$6.8M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025n/an/a
FY2024−$37.2Mn/a
FY2023−$32.8Mn/a
FY2022−$38.3Mn/a
FY2021−$53Mn/a
FY2020−$22.9Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY25−$6.8Mn/an/a
Q3 FY25−$11.1Mn/an/a
Q4 FY24−$8.8Mn/a−$37.2M
Q3 FY24−$7.3Mn/a−$38.3M
Q2 FY24−$9Mn/a−$36.2M
Q1 FY24−$12.1Mn/a−$36.7M
Q4 FY23−$9.9Mn/a−$32.8M
Q3 FY23−$5.2Mn/a−$30.2M
Q2 FY23−$9.5Mn/a−$30.4M
Q1 FY23−$8.2Mn/a−$30.8M
Q4 FY22−$7.4Mn/a−$38.3M
Q3 FY22−$5.4Mn/a−$45.3M

Against its peers

Companies in Drug Manufacturers - General nearest Elicio Therapeutics' size, closest first, today.

CompanyFree cash flow yield
ELTXElicio Therapeuticsn/m
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
NATRNatures Sunshine Products8.5%
ARVNArvinas−43.7%
Peer median8.5%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Elicio Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.